Thank you, Lars.
Go ahead. The stage is yours.
Absolutely. Thank you, and welcome everybody else. Just give me a second to share my presentation. Should not take very long. There we go. Yes. So, welcome everybody. Happy to give you a quick update on BioInvent. We are focusing on the next generation of immunotherapy for cancer, and listed on the Stockholm Stock Exchange. That is why we have this disclaimer here. Our main focus is on the new standard of care for recurring ovarian cancer, which is a very high unmet need, and therefore also a quite interesting commercial opportunity. I will come back to all details a little bit later in my presentation. Before I go there, because there might be still somebody who does not know BioInvent, so we are a Swedish clinical stage biotech company developing the first in-class immune modulating antibodies to treat cancer. We currently have four ongoing clinical trials.
I will come back to details there a little bit later. The company is quite integrated, which means we do the discovery of the targets and the antibodies. We also do our own manufacturing and formulation, and then of course clinical development. We are listed on the NASDAQ OMX in Stockholm, and have actually a quite broad international shareholder base. Before I go into more details regarding our lead program, BI-1808, just to give you a quick overview of what we are currently dealing with. So two programs really. One is called BI-1808, targeting a structure that is called TNF receptor two. There we have two parallel developments ongoing. One is what I already mentioned at the beginning, in ovarian cancer, to be precise, recurring ovarian cancer. There we just had some very interesting data at ESMO, International Conference for Cancer.
The other development track that we have is in a disease called CTCL, which is a T-cell lymphoma, where we also have very strong data as a single agent. That will be my main focus today, BI-1808, and there specifically ovarian cancer. To mention it here also as well, we have a second program, BI-1206, targeting a structure called FcγRIIB. There we are in non-Hodgkin lymphoma and non-small cell lung cancer, and uveal melanoma, and I'll come back to that later a little bit more in detail. Now on TNF receptor two in ovarian cancer first, but then also T-cell lymphoma. We had recently quite some recognition and interest in that program because we published the mode of action in a high-ranked scientific journal. I will not spend too much time here, but it's a very interesting new mode of action.
We work in the tumor microenvironment and by depleting T regulatory cells, but also activating the so-called myeloid cells, and that leads to basically to the recruitment of activated CD8- positive T- cells. So very powerful mechanism, and we demonstrated that in single agent activity, but also in a very strong synergy with anti-PD-1. I will also not spend too much time here. We basically, on the preclinical work that we have done, we started two tracks, part A and part B, single agent as well as in combination with pembrolizumab, and I will come back to the data in a moment, and later we'll also talk about part C, which is the next step to be initiated.
On the part A, we saw a very strong single agent activity in solid tumors, and obviously, when you do oncology development or oncology therapeutic development, you end up with heavily pretreated patients, end of the line patients, and in those patients, we saw complete responses, partial responses, stable disease. So really, really nice data. Just to give you a little bit of a flavor, and I don't have the time today to go through all the patients, this was a ovarian cancer patient, 63 years old, heavily pretreated, and after a couple of weeks, we had a complete response. Also, we could see that the antibody was doing its job in this patient, basically by depleting the T regulatory cells. Another example is this one, which is another so-called solid cold tumor, GIST, and that was a patient 55 years old.
He had 12 previous lines of therapy, so everything what could be used. Also this resulted in a very nice response, and that was initially a robust partial response, but then later we could confirm by biopsy that that's probably also a complete response. What you can see very nicely on the right-hand side, pre-dose in the tumor microenvironment, you don't see any CD8- positive T- cells. Once you treat with our antibody, all these green dots show that CD8- positive T- cells infiltrated the tumor microenvironment, and those are the immune cells that do the work and eliminate the cancer cells. That was the single agent piece. Based on the preclinical observations, we also started then combination with pembrolizumab, and that's the data set that we just presented at ESMO, and we got the Best Poster Award in the section of the investigational immunotherapy.
At the time, we had 34 evaluable patients in both subtypes of recurring ovarian cancer. What is very important to remember is that those patients also were heavily pre-treated, so we had four median prior lines, and still got this very nice response, 25% overall response compared to pembro alone, which is just 8%, had complete response, partial responses, and stable disease. Very importantly, we saw a very interesting progression-free survival endpoint of 10.3 months under iRECIST, and RECIST, that would be 4.1 months, which is also better than pembro alone. That is a very strong dataset. I think it's important also to point out the difference, and that this study population that we used there was much heavier pre-treated than the KEYNOTE-B96 population. That is where pembro was tested.
This patient population where pembro was tested were less heavily pre-treated, had less anti-PD-1 before, and in all comparisons, I think this patient population that we had was heavily pre-treated and a very difficult patient population to get responses. That is another summary. Basically, on the left-hand side, what you see here is the single-agent activity, which was in recurring ovarian cancer, 6% compared to pembro, 8%, so it's more or less the same. In combination, we get it up to [inaudible], which is actually a very strong value. Safety was also very good. No safety issues, basically excellent safety profile in the doublet combination as well as in the single-agent treatment. What we're trying to do is to show in the next step that we are better actually than the recently approved standard of care, which is here.
Of course, what we're focusing on is recurring ovarian cancer, that is this track here. The recently approved standard of care is pembro plus paclitaxel. What we want to do in the next step is to show if we add 1808 to it, that we will get a better progression-free survival as well as a higher objective response. That is to be started in early next year. What is happening as well in this disease indication is there's quite some competition from ADCs, and we don't have the time to discuss here in detail. Maybe we can do it later during the Q&A. ADCs is basically targeted chemotherapy, so has still a significant toxicity. It's biomarker restricted, and all the patients will become resistant at some time point.
That means once you have used one ADC, you can't use the same ADC again with a similar payload or targeting moiety. We are not really competing with ADCs because we have a complementary, completely differentiated mode of action, which means we can go before an ADC, alongside an ADC, and after an ADC. So the commercial opportunity based on the high unmet need is significant. In a very conservative estimate, we have forecasted SEK 1.7 billion, which is the base case for the current target product profile. The timelines just listed here, p hase II part A has been done, p hase II part B is ongoing. We presented more or less the final data at ESMO, so there's still one or two patients that we will follow up, and there will be some later update again, maybe in the press release. We will see.
We got Fast Track designation, which is really, really good. Next year, we'll start the combination and comparison to the standard of care, and we'll go for Breakthrough Therapy Designation, and then the next step could be already a pivotal study for this indication. Very briefly then on the other indication in cancer, which is T-cell lymphoma, there we also have very strong single-agent activity of BI-1808. You see a PTCL patient here on this side, where we saw after six prior lines of treatment, also heavily pre-treated, a very nice response. Those ganglia completely disappeared after nine weeks. Then here, this is a typical CTCL patient. We have those skin lesions that healed very nicely after a couple of weeks. Regarding the mechanism of action, it's very similar what we see in the solid cancer.
That means we target directly the tumor T-cells, but also see infiltration of immune cells into those skin lesions. We have done both single agent as well as the combination. Currently, we're running the dose optimization, and the latest data set that we presented at EHA is here. This is the single agent in a heavily pre-treated patient population, nice objective response, good disease control, more than 90%. Also already showing long-lasting complete responses, which is nice. Then on the right-hand side, you see the combination with pembro, which is not adding much. Going forward, we'll focus on the single agent. Based on the data, we did some comparison with the landscape that is out there, and you basically have efficacy on this side, and this is toxicity leading to discontinuation. Where you want to be is the higher right quadrant, and that's where we are.
There's only one drug that has more efficacies, which is this one, brentuximab, which is also very toxic and very limited because you can only treat patients that have CD30 as a marker. At the end, just very briefly on the anti-FcγRIIB BI-1206 side. We're developing this in solid tumors, in non-small cell lung cancer, and uveal melanoma. Saw some very interesting responses in a phase I end-of-the-line study. Here's a partial response in uveal melanoma. Very nice, very solid. This is an example of a complete response in cutaneous melanoma. What we're trying to do is really to move pembro up, because it's in combination with pembro, and we'll see. The next step there is the first readout during the first half of next year. We also have very strong data of BI-1206 in non-Hodgkin lymphoma. We also published that already.
Very nice objective response, high numbers of complete responses, disease control of 100%, almost no toxicity, which is also very, very important. This antibody, I think also it's important to mention, is a subcu version, which is very easy to apply. At the end, just very briefly about the key expected milestones. For BI-1808, which is our value-driving lead program, we have shown the data of the milestones in 2026. The next step will be then to complete the dose optimization for the CTCL, dose optimization which is ongoing, and then to kick off the comparison between the standard of care in recurring ovarian cancer. There, we will have the first data during the second half of 2027.
Then BI-1206, targeting FcγRIIB, the next milestone for non-Hodgkin lymphoma is getting ready for pivotal triplet, but this will not be done by ourselves, so we are currently actively looking for a partner. We also obviously await the first readout for the phase II-A data with KEYTRUDA in first line. Then potentially, there could be a start of phase II-B, but in general, our thinking currently is really to partner BI-1206 and to going forward to focus more on BI-1808. That is the end of my presentation. Thank you very much.
Thank you very much, Martin. A lot is about BI-1808, of course, and as I've gathered from your quarterly report, you also aim to do some restructuring to in part take in some fresh money and to reduce cost in order to facilitate this. Can you tell me a little bit about what does it mean when you streamline the organization?
Yeah, basically just to reduce the headcount since we are now We started with a relatively large portfolio. You might remember since we met already before that we had two other assets that we paused during the summer last year, not because we didn't get good data, but we said we should focus really on the most promising one, which is clearly BI-1808. At that time, we were focusing on both BI-1808 and BI-1206 because we didn't know at that time which will be the frontrunner, and now we know it's 1808. BI-1206, we're trying to partner, and then, of course, we also can reduce the headcount because we will have less programs to develop. Basically, what we mentioned, I think, in the press release and also in the report, we'll reduce up to 20 FTEs.
We're currently in the process of it, and of course, this is never a nice thing to do, but necessary in order to use the cash in the best possible way and to really get to the goal with BI-1808 to show that it's better than the standard of care.
Right. I see. You also have, I mean, looking at last year, for instance, you had quite a good positive cash flow with payments coming in from partners, et cetera. What is the outlook for 2027? You have a lot of readouts of data. Do you have any expected cash flow coming as well?
Yeah, as I said, I can just repeat what I already mentioned. We are trying to partner BI-1206, and hopefully that could contribute to some non-dilutive funding. That would be, of course, welcome from various aspects, but that is something that we are working on, basically. Yeah.
Right. You mentioned ESMO earlier and quite rapidly, but as I gathered, you won actually an award during that conference, the Best Poster Award. Can you just tell me what were the rationale for the jury to choose you?
Yeah, I think, as I mentioned, BI-1808 is really a completely new mode of action. We are the first one developing it, which of course is also challenging in a way, because if you develop something which is first in class, you are the one that develops it first, which means it is also higher risk, and also then the expectation of data by potential partners as well as investors is higher, because people do not know the mechanism yet, and we are the ones that are proving it. But that was recognized by the jury because it could be the next generation KEYTRUDA, basically, yeah? If it is, of course, all driven by data. But that was the recognition by the jury that they say: Okay, you have something completely new, and the data so far that we have is strong.
That is interesting. As you say, there might be more risks involved with being first in class. There is no—
Absolutely.
—comparison. Maybe there is a smaller basis for, let us say, proof of concept and so on. There is some upside to it as well, I suppose.
Yeah.
For instance, with pricing. So you have this SEK 1.7 billion peak sales estimate.
Yeah.
Can you perhaps give some flavor on how you arrive at that number?
Yeah. We didn't do it ourselves. We used an external party, EVERSANA. It is one of the providers in that space, really doing interviews with payers, with KOLs, and based on that, we came to that number. It's a conservative estimate, and it's of course only covering recurring ovarian cancer. It's not covering T-cell lymphoma. That is a market in itself, which is around half a billion, and I didn't mention it here, but it's a much smaller market because an orphan indication. Then I think what could also come on top of it is that we see, and that's data that is not in the public domain yet, and we'll release it at some time point, hopefully next year, that we see also nice signals in other solid cold tumors, and that's where we're trying to position ourselves. I think CTCL is interesting.
That could be a validator, but it's obviously not the biggest market, although the unmet need is also very high there for a safe, efficacious drug. But that could be maybe the first one together with a partner that could hit the market, and since it's an orphan indication, it would also not be price sensitive, right? I think from a strategy, that would make a lot of sense.
That sounds interesting. A final question. I remember last time, in a little bit less than a year ago, we talked a little bit about assets beyond your two main tracks—
Yeah.
—BI-1808 and BI-1206. Now that you're focusing even more on BI-1808, does that mean that the rest of the portfolio is also put on a bit of a slow burner, or will you continue to develop those assets?
Yeah. We still have some preclinical research discovery ongoing, but the main focus clearly is on BI-1808, and that's how it goes because as a small company, you cannot run everything in parallel all the time. We did that at the beginning in order to really figure out which is the main value driver, and now we feel it's BI-1808. Let's say we do some partnering around BI-1808 or BI-1206, that of course would then also free up resources to return to BI-1607 or BI-1910, the ones that we put on pause, or maybe something even earlier. Those are not bad programs. They were just much earlier, and based on cash runway, market situation, et cetera, we made a choice to really focus on the main value driver.
That could change again, and that's not that the others are completely gone, so they could be restarted in case that would make sense, right? To be very clear, the number one focus is now for the foreseeable future, BI-1808.
Right. Of all the readouts here in 2027, is there one data point in particular that you would deem more important than others?
Yeah. It's obviously the data points around BI-1808, so there will be the dose optimization finalization data point for CTCL. That would be during the first half. Then, of course, the most important is the first readout regarding the comparison to the standard of care in recurring ovarian cancer. That's the number one value driver, very clearly.
Very good. Thank you for participating tonight, Martin, and good luck with your projects.
Thank you very much.